Interview: Enrico Allievi – Director, Assosalute, Italy
Enrico Allievi, President of the Italian OTC (Over The Counter) association, Assosalute, talks about the state of the OTC market in Italy, as well as the association’s role in creating…
Assogenerici (National Association of Generic Drugs Industries) is the official representative body of the industry of generic drugs and biosimilars in Italy, at the forefront in providing medicines at affordable prices and high quality for millions of citizens, helping to boost competition and innovation in the pharmaceutical sector. Associated companies both small and medium corporations for a wide range of drugs, by perfusion with Galen to traditional generics to cutting biosimilars, is distributed in pharmacies at public hospitals.
Established in 1993, Assogenerici represents over 50 pharmaceutical companies. The companies represented in Assogenerici provide 10,000 direct jobs in Italy over the important induced, highly specialized. Generic drugs generate over € 400 million of savings per year for the NHS and for patients, helping to ensure patient access to essential drugs releasing at the same time, valuable resources for new and expensive drug therapies.
Assogenerici plays an important advisory role in the Italian health sector. Assogenerici and its members are working with the Italian and European institutions to develop sustainable solutions for pharmaceutical care and to increase the competitive strength of Italy in the world pharmaceutical market.
Passeggiata di Ripetta, 22 – int. 1 – 00186 – Roma
Tel: +39.06.59.60.53.24
Fax: +39.06.54.31.323
E-mail: info@assogenerici.it
Posta Elettronica Certificata: assogenerici@pec.
Web: assogenerici.it
Enrico Allievi, President of the Italian OTC (Over The Counter) association, Assosalute, talks about the state of the OTC market in Italy, as well as the association’s role in creating…
Dr. Anna Maria Porrini, President of Boehringer Ingelheim Italy shares her vision for the company, how she intends to achieve it and where she sees opportunities for the company’s success…
Antonino Reale, who has managed Daiichi-Sankyo Italy for the last 12 years, explains the reasoning and strategy behind the company’s almost total restructuring in 2013, including how this has given…
Gabriele Baccelli shares his journey of setting up a lean organization at a time of crisis, the management decisions he took in order to navigate this environment and how he…
The Italian Medicines Agency, AIFA, sits at a crossroads. Its Director-General Prof. Luca Pani discusses the apparent contradiction in the agency’s mission at a time of constricting budgets and expensive…
Thibaud Eckenschwiller, VP & Managing Director for Ipsen Italy, shares his impression of the Italian pharmaceutical market after one year in office, how he is applying Ipsen’s global strategy to…
Alessandra Modenese Kauffmann, General Manager of the Swiss Chamber of Commerce, shares her insights into the relationship between Italy and Switzerland, the Chamber’s efforts to foster trade between the two…
Massimiliano Rocchi, Managing Director at Accord Italy shares his view on the story behind Accord’s success in Europe, the key differentiating elements for any generics company in a market with…
Massimo Scaccabarozzi, President of Farmindustria, talks about the potential of the pharmaceutical industry in Italy, the changes which need implementing to realize that potential and his vision for the industry’s…
Leonardo Vingiani, Director of Assobiotec, discusses how the country’s biotech industry has evolved since 2009, what areas still need improving and the enormous progress which has been made in unlocking…
Jörg Buck, the Executive Director of the Italian-German Chamber of Commerce discusses the close trade relationship which ties the two countries together, how the business environment in Italy is evolving…
Sicily plays a major role in a plethora of gangster stories, whether real or fictional; the initiated also know that it is the land of incredibly well preserved Greco-Roman sights…
See our Cookie Privacy Policy Here
